Semiannual Securities Report — FY2026 H1
What OncoTherapy Science,Inc. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-09View the original on EDINET
How much it says
49Typical
What moved here
23named for the first time
Its own wording
50terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, the Company recorded an operating loss of ¥568 million, mainly due to the recognition of R&D expenses, and an interim net loss attributable to owners of the parent of ¥574 million. Cash and cash equivalents stood at ¥2,083 million at period-end. Investing activities were limited, while financing activities included proceeds from the issuance of shares.
Komori's summary of this document, not the document's own words.49Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
54
Typical
36
Thin
75
Very detailed
0
Almost nothing
68
Detailed
27
Almost nothing
31
Thin
60
Detailed
55
Typical
50
Typical
R&D spend3億円Money spent making new things.
Cash left over-5億円Cash from the business, less what went into equipment.
Spent on equipment61百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.